PT-141 vs Melanotan II: Which Is Better for Libido? BioHarmony head-to-head comparison
Head-to-Head Comparison

PT-141 vs Melanotan II: Which Is Better for Libido?

Should I use PT-141 or melanotan II?

Reviewed 09/07/2026

PT-141 scores 5.4 and melanotan II 4.6, and both land in the neutral tier. PT-141 is the defensible one. It targets the brain receptor that drives desire, it comes through a pharmacy, and it has randomized evidence. Melanotan II activates every melanocortin receptor, so tanning, melanoma reports and rhabdomyolysis ride along with the libido effect.

  • PT-141 5.4, melanotan II 4.6. Both are neutral tier, so neither is a compound to reach for casually.
  • Same family, different aim. PT-141 is weighted to MC4R in the hypothalamus. Melanotan II hits MC1R, MC3R, MC4R and MC5R at once.
  • Melanotan II's libido subrating is 6.1 against PT-141's 5.5, and Nick's own experience matches that ordering.
  • The reason to pick PT-141 anyway is the safety column: melanotan II's case record includes melanoma, rhabdomyolysis, PRES, renal infarction and priapism.
  • PT-141 is the only FDA-approved drug for acquired low sexual desire in premenopausal women. Melanotan II has no approved product anywhere and carries active regulator warnings.
  • Cost runs the other way. Melanotan II is an ESTIMATE of $25 to $55 a month from research-chemical vendors, PT-141 an ESTIMATE of $80 to $200 through telehealth.
  • Only skin darkening separates them on benefit, and the same receptor that darkens skin also darkens moles.

At a Glance

PT-141 (Bremelanotide)
Option A

PT-141 (Bremelanotide)

5.4 / 10 🤷 Neutral
Upside
  • Efficacy 3.5
  • Breadth 3.5
  • Evidence 4.3
  • Speed 4.0
  • Durability 2.3
  • Bioindividuality 2.8
Downside
  • Safety Risk 2.5
  • Side Effects 3.5
  • Cost 3.0
  • Effort 3.3
  • Opportunity Cost 2.8
  • Dependency 2.0
  • Reversibility 2.5
Best at:
  • Libido 5.5
  • Social Bonding 2.5
  • Mood 2.2
  • Hormonal 1.6

MC4R-weighted melanocortin agonist, FDA-approved as Vyleesi for premenopausal HSDD. BioHarmony 5.4, neutral tier.

Read full BioHarmony report →

Melanotan II
Option B

Melanotan II

4.6 / 10 🤷 Neutral
Upside
  • Efficacy 3.8
  • Breadth 3.2
  • Evidence 3.0
  • Speed 4.2
  • Durability 2.0
  • Bioindividuality 3.0
Downside
  • Safety Risk 3.7
  • Side Effects 3.8
  • Cost 2.5
  • Effort 3.0
  • Opportunity Cost 2.8
  • Dependency 2.0
  • Reversibility 2.3
Best at:
  • Skin Beauty 6.4
  • Libido 6.1
  • Body Composition 5.0
  • Antioxidant 5.0

Non-selective melanocortin agonist hitting MC1R through MC5R. No approved product anywhere. BioHarmony 4.6, neutral tier.

Read full BioHarmony report →

Head-to-Head Verdict

Use CaseWinnerRationale
LibidoTieMelanotan II 6.1 against PT-141 5.5, so the raw effect favors melanotan II, and both reports credit its higher MC4R affinity. The evidence runs the other way: PT-141 has two Phase 3 trials in about 1,267 women (Kingsberg 2019) behind an FDA approval, against melanotan II's 19-man crossover (Wessells 2000). Call it even and let safety break the tie.
Skin BeautyMelanotan IIMelanotan II 6.4 against PT-141 1.6, the widest gap in the matrix. Dorr 1996 confirmed measurable pigmentation from short low-dose subcutaneous MT-II. PT-141 was engineered to minimize tanning, so its pigment changes count as an unwanted side effect. Winning this row is not the same as being worth using for it: the MC1R activation that darkens skin also darkens nevi.
MoodPT-141 (Bremelanotide)PT-141 2.2 against melanotan II 1.5, and both numbers say the same thing. Neither is a mood tool. PT-141 edges ahead only because MC4R sits in reward circuitry, which makes a mood angle mechanistically plausible. No trial has tested it as an antidepressant, and the same pathway is implicated in anhedonia (Pfaus 2022), so the effect could go either way.
Social BondingPT-141 (Bremelanotide)PT-141 2.5 against melanotan II 1.5. Clinics stack PT-141 with oxytocin and market a connection effect, and melanocortin signaling does shape social behavior in animals. There is no controlled human bonding endpoint on either side, so this rests on mechanism and anecdote. A 1.0 point gap between two low scores is not a reason to buy anything.
CardiovascularTiePT-141 1.3 against melanotan II 1.5, both floor scores. PT-141 is net negative: every dose transiently raises blood pressure, about 1 percent of trial participants recorded 180/110 or higher per the Vyleesi label, and cardiovascular disease is an absolute contraindication. Melanotan II adds a renal infarction case report (Peters 2020).
DepressionTieBoth score 1.5. No trial on either side treats depression as an endpoint. PT-141's melanocortin-4 pathway is mechanistically tied to anhedonia, which argues for caution rather than benefit. Melanotan II has no meaningful direct human evidence here at all. Same score, same conclusion, and the mechanism gives no reason to expect one to outperform the other.
EnergyTiePT-141 1.4 against melanotan II 1.5. Fatigue is listed among PT-141's side effects, so the direction is negative rather than neutral. Melanotan II's early human work reports yawning and nausea (Dorr 1996) rather than any stimulant effect. A 0.1 gap between two floor scores decides nothing.
LongevityTiePT-141 1.2 against melanotan II 1.5. No longevity or healthspan data exists for either. PT-141 is an on-demand sexual-function drug with a monthly dose cap of eight. Melanotan II has no long-term controlled human safety data, which is a different problem from having neutral longevity data: chronic exposure is the exact scenario its melanoma signal (Hjuler 2014) makes hardest to defend.

Cost Comparison

InterventionMonthly CostNotes
PT-141 (bremelanotide)$80 to $200ESTIMATE, priced 2026-09-07, telehealth channel, at the 1.75 mg label dose. Telehealth compounded bremelanotide runs about $80 to $200 a month for on-demand use inside the label's cap of 8 doses per month. Branded Vyleesi autoinjectors are about $250 each, so a person using the brand at any real frequency pays several times the compounded figure.
Melanotan II$25 to $55ESTIMATE, priced 2026-09-07, research-chemical channel, at a variable dose. A 10 mg vial from a mid-tier research vendor runs $25 to $45, and a community loading cycle uses roughly one vial a month plus about $10 of bacteriostatic water, syringes and swabs. There is no approved product, so this is a vendor price rather than a pharmacy price.
The differenceMelanotan II is roughly $55 to $145 a month cheaperMelanotan II costs a fraction of PT-141, and the gap is not a bargain. The $25 to $55 buys material from an unlicensed vendor selling vials labelled not for human use, with purity verification required and a certificate of analysis on you to obtain.The $80 to $200 for PT-141 buys a prescriber, an approved reference product and a known dose. Price is the one column melanotan II wins outright, and it wins it by removing every check the higher price pays for.

When to Switch

Both peptides announce themselves inside about an hour, so the first dose tells you whether you respond, not whether it is worth continuing. The assessment windows differ: melanotan II is judged at 4 weeks, PT-141 at 8, and each reaches what its report calls full effect at the same mark. Judge melanotan II at 4 weeks, PT-141 at 8, and treat anything before that as noise.

Move from melanotan II to PT-141 when the libido effect is the reason you are using it at all, when a dermatologist flags a changing mole, when nausea or blood-pressure symptoms show up, or the moment you want a supply chain you can verify. That move trades a 6.1 libido subrating for a 5.5 and buys back the tanning, melanoma and rhabdomyolysis exposure. Move the other way, from PT-141 to melanotan II, only if you have run the label dose of 1.75 mg through a full 8-week window, found the response too weak to matter, and accept that you are choosing a stronger effect from an unapproved vendor with worse documented harms.

Do not overlap them. They are redundant at MC4R, so running both stacks the same nausea, flushing and blood-pressure burden with no additional mechanism to show for it, and PT-141's own label caps dosing at once in 24 hours and 8 times a month.

Who Should Pick What?

Premenopausal woman with diagnosed hypoactive sexual desire disorder

PT-141 (Bremelanotide)

This is the only population where either compound has an approved indication. Two Phase 3 trials in about 1,267 women met co-primary endpoints for desire and distress (Kingsberg 2019). Expect a modest result: the desire gain fell below the commonly cited clinically meaningful threshold and satisfying sexual events did not rise (Spielmans 2021).

Man who did not respond to a Viagra-type drug alone

PT-141 (Bremelanotide)

PT-141 acts centrally on desire rather than on blood flow, so it adds a different mechanism instead of a second dose of the same one. Rosen 2004 produced erectile responses in Viagra non-responders, and Diamond 2005 showed an additive response when it was combined with sildenafil. The male evidence is Phase 2 only, so treat it as a reasonable trial rather than a proven path.

Experienced user who wants the strongest libido effect and understands the risk

Melanotan II

Melanotan II's libido subrating is 6.1 against PT-141's 5.5, and its higher MC4R affinity is why. This only holds for someone with a dermatologist watching their moles who treats it as a short initiation tool rather than a chronic product. I use it that way and long-term safety is still my standing worry.

Anyone whose actual goal is a tan

Tie

Neither. Melanotan II is the only one of the two that tans, at a 6.4 skin-beauty subrating, and cosmetic tanning is the weakest possible reason to accept the melanoma and dysplastic-nevus signal that comes from the same receptor (Hjuler 2014). PT-141 was designed to strip the tanning out, so it does not serve this goal at all.

Personal or family history of melanoma, or many atypical moles

Tie

Neither. Melanoma history is a listed contraindication on both sides, and atypical or changing moles are listed on melanotan II specifically. Chronic melanocortin-1 activation drives melanogenesis (Bohm 2025), and PT-141 touches MC1R even though it is weighted to MC4R. Skip both and take the question to a dermatologist first.

Uncontrolled hypertension or known cardiovascular disease

Tie

Neither, and this one is absolute. Uncontrolled hypertension and known cardiovascular disease are both absolute contraindications for PT-141 because every dose raises blood pressure. Uncontrolled blood pressure is on melanotan II's list too, alongside kidney disease, seizure disorder, prior priapism and sickle-cell disease.

Cost is the binding constraint

PT-141 (Bremelanotide)

The cheaper option is the wrong call here. Melanotan II runs an estimated $25 to $55 a month against PT-141's estimated $80 to $200, and the entire saving comes from removing the prescriber, the approved reference product and the verified dose. If the $80 floor is out of reach, the answer is to use neither rather than to buy the unverified one.

Research Highlights

  1. Mechanism Difference

    PT-141 and melanotan II are redundant, not complementary. Both are melanocortin agonists and both act at MC4R, which is where the libido effect of either one comes from. Running them together stacks the same nausea, flushing and blood-pressure load with no second mechanism behind it.What separates them is aim. PT-141 is weighted to MC4R in the hypothalamus, raising dopamine signaling in sexual-motivation circuitry. Melanotan II is non-selective across MC1R, MC3R, MC4R and MC5R, so MC1R-driven melanogenesis arrives whether you wanted a tan or not.

  2. Safety Comparison

    Melanotan II carries the harsher record. Its verified case reports include melanoma (Hjuler 2014), rhabdomyolysis after a 6 mg injection (Nelson 2012), posterior reversible encephalopathy syndrome (Kaski 2013), renal infarction (Peters 2020) and ischemic priapism (Mallory 2021).PT-141's downside is tolerability plus a population-specific cardiovascular limit. Nausea hits about 40 percent of users and drives an 18 percent discontinuation rate, and every dose transiently raises blood pressure. Both rule out pregnancy, breastfeeding, melanoma history and unverified vials.

  3. Cost Comparison

    Melanotan II is the cheap one. An estimated $25 to $55 a month covers a 10 mg research-vendor vial plus bacteriostatic water and supplies, against an estimated $80 to $200 a month for telehealth compounded bremelanotide inside PT-141's cap of 8 doses. Both figures were priced 2026-09-07.Branded Vyleesi autoinjectors run about $250 each, which is what the approved product actually costs. The $55 to $145 monthly gap is the price of a prescriber, a known dose and a supply chain that does not require you to commission your own certificate of analysis.

  4. Editorial Verdict

    PT-141 scores 5.4 and melanotan II 4.6, both neutral tier, and the gap understates how differently they should be treated. PT-141 is the only FDA-approved drug for acquired low sexual desire in premenopausal women, and its effect is real but small.Melanotan II produces the stronger libido response and the only genuine tanning effect, at a 6.1 and a 6.4 subrating. It buys those with a case record that includes melanoma, rhabdomyolysis and PRES. Pick PT-141, or pick neither.

  5. Evidence Quality

    PT-141 has the better evidence base by a wide margin, and it is still modest. Two Phase 3 randomized trials pooling about 1,267 premenopausal women earned the 2019 approval (Kingsberg 2019), and an independent non-industry re-analysis found the desire gain below threshold with no rise in satisfying sexual events (Spielmans 2021).Melanotan II's human record is small early trials plus case reports. Dorr 1996 tested three male volunteers. Wessells 2000 covered 19 men. There is no long-term controlled human safety data, which is why its evidence subscore sits at 3.0 out of 5.0.

Frequently Asked Questions

Is PT-141 just melanotan II with the tanning removed?
That is the pitch, and roughly the design intent. Both are melanocortin agonists acting at MC4R, so the pair is redundant rather than complementary.PT-141 is weighted to MC4R in the hypothalamus. Melanotan II activates MC1R, MC3R, MC4R and MC5R together, and MC1R is the skin receptor that drives the tan. The libido effect came out weaker too: 6.1 against 5.5.
Which one actually works better for libido?
Melanotan II, on effect size. Its libido subrating is 6.1 against PT-141's 5.5, and both source reports credit its higher MC4R affinity.PT-141 has the better proof: two Phase 3 trials and an FDA approval, though the desire gain fell below the clinically meaningful threshold and satisfying sexual events did not increase (Spielmans 2021).
Is melanotan II dangerous?
The case record is serious enough to treat as decisive. Verified reports include melanoma (Hjuler 2014), rhabdomyolysis after a 6 mg injection (Nelson 2012), PRES (Kaski 2013), renal infarction (Peters 2020) and ischemic priapism (Mallory 2021).Case reports cannot prove causation, which is why the safety subscore is 3.7 out of 5.0 rather than the ceiling. There is no long-term controlled human safety data at all.
Can I use both together?
No. They are redundant at MC4R, so stacking them multiplies nausea, flushing and blood-pressure load without adding a mechanism. PT-141's own label caps dosing at one dose in 24 hours and 8 doses a month, and melanotan II contributes its own MC4R activity on top. If you are switching, stop one before starting the other.
Who should not use either one?
Anyone with a personal or family history of melanoma, anyone with atypical or changing moles, anyone pregnant or breastfeeding, and anyone who cannot verify what is in the vial.PT-141 adds absolute contraindications for uncontrolled hypertension and known cardiovascular disease, plus a naltrexone interaction. Melanotan II adds kidney disease, seizure disorder or severe migraine, prior priapism and sickle-cell disease, and it needs baseline full-body mole mapping first.
How much does each cost?
Both figures are estimates priced 2026-09-07. Melanotan II runs about $25 to $55 a month: a 10 mg research-vendor vial at $25 to $45 plus about $10 of bacteriostatic water and supplies. PT-141 runs about $80 to $200 a month for telehealth compounded bremelanotide, and branded Vyleesi autoinjectors are about $250 each. The cheaper option is the unlicensed one.
How long before I know whether it is working?
Both are noticeable within about an hour of a dose, so responsiveness is obvious immediately. The assessment windows differ. Melanotan II is judged at 4 weeks and PT-141 at 8 weeks, and each reaches what its report calls full effect at that same mark. A large minority simply do not respond to PT-141, so a flat 8 weeks is a real answer rather than a dosing problem.
Has Nick used these?
Both, at different intensities. He is actively using melanotan II and rates it 5.9, calling it powerful and fast acting, with an orange-toned tan he does not love and long-term safety as his main worry. PT-141 is in his rotation only occasionally, rated 6, and he found the libido response clearly weaker than melanotan II's with nausea appearing when he nudged the dose up.

Evidence Sources

Glossary

Quick reference for the medical and technical terms used in this comparison.

MC4R Melanocortin-4 Receptor
The brain receptor tied to appetite and sexual motivation. PT-141's main target and the receptor both compounds share, which is why the pair is redundant.
MC1R Melanocortin-1 Receptor
The skin-pigment receptor. Activating it produces the tan, and the same activation is what can darken existing moles.
MC3R Melanocortin-3 Receptor
A third melanocortin receptor involved in energy balance and feeding. Both compounds touch it, melanotan II more broadly.
MT-II Melanotan II
The synthetic non-selective melanocortin peptide sold as tanning injections or nasal sprays. No approved product exists anywhere.
HSDD Hypoactive Sexual Desire Disorder
Persistent low sexual desire that causes distress. The condition PT-141 is approved to treat in premenopausal women.
MCID Minimal Clinically Important Difference
The smallest change a patient would actually notice. PT-141's desire effect fell below the commonly cited MCID.
SSE Satisfying Sexual Events
The count of satisfying encounters, the harder trial endpoint. It did not rise versus placebo in the PT-141 trials.
PRES Posterior Reversible Encephalopathy Syndrome
A rare neurologic emergency, reported in a melanotan case (Kaski 2013). One of the harms that separates melanotan II from PT-141.
PDE5 inhibitor Phosphodiesterase Type 5 Inhibitor
The Viagra and Cialis drug class, which acts on blood flow rather than desire. PT-141's central mechanism is why the two can stack.
Nick Urban

Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

I have used both of these peptides personally, melanotan II actively and PT-141 occasionally

Reviewed Sep 7, 2026 · next review Dec 6, 2026

Find which one fits your biology

Take the BioHarmony Quiz